This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
stock-price-movement: Archive
What Makes Prothena (PRTA) a New Buy Stock
by Zacks Equity Research
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PRTAPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Nomura Research Institute (NRILY) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Nomura Research Institute (NRILY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
NRILYPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Transcat (TRNS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Transcat (TRNS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TRNSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Should You Buy Heritage Insurance (HRTG) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
HRTGNo Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Allegion (ALLE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ALLEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
VCYTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
What Makes Ponce Financial (PDLB) a Good Fit for 'Trend Investing'
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Ponce Financial (PDLB) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
PDLBPositive Net Change
price-performance stock-price-change stock-price-movement
Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, ArriVent BioPharma, Inc. (AVBP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
AVBPPositive Net Change
price-performance stock-price-change stock-price-movement
Here's Why Momentum in Belden (BDC) Should Keep going
by Zacks Equity Research
Belden (BDC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
BDCPositive Net Change
price-performance stock-price-change stock-price-movement
Here's Why Momentum in First Savings Financial (FSFG) Should Keep going
by Zacks Equity Research
First Savings Financial (FSFG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
FSFGPositive Net Change
price-performance stock-price-change stock-price-movement
Here's Why Momentum in Coca-Cola European (CCEP) Should Keep going
by Zacks Equity Research
Coca-Cola European (CCEP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
CCEPPositive Net Change
price-performance stock-price-change stock-price-movement
Here's Why Momentum in Sabesp (SBS) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
SBSPositive Net Change
price-performance stock-price-change stock-price-movement
Recent Price Trend in StoneX Group (SNEX) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, StoneX Group (SNEX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
SNEXPositive Net Change
price-performance stock-price-change stock-price-movement
Jushi Holdings Inc. (JUSHF) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Jushi Holdings Inc. (JUSHF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
JUSHFPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Inseego (INSG) Rating Upgrade to Buy
by Zacks Equity Research
Inseego (INSG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
INSGPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Alpine Income (PINE) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Alpine Income (PINE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PINEPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy
by Zacks Equity Research
Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FATEPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
by Zacks Equity Research
Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CKPTNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About First Financial (FFBC) Rating Upgrade to Strong Buy
by Zacks Equity Research
First Financial (FFBC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FFBCPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Kratos (KTOS) a New Buy Stock
by Zacks Equity Research
Kratos (KTOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
KTOSPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
RCM Technologies (RCMT) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
RCM Technologies (RCMT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
RCMTNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Sun Hung Kai Properties (SUHJY) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Sun Hung Kai Properties (SUHJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SUHJYPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Pediatrix Medical Group (MD) Rating Upgrade to Strong Buy
by Zacks Equity Research
Pediatrix Medical Group (MD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
MDPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
CommScope (COMM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
COMMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Deckers (DECK) Just Overtook the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
DECKPositive Net Change
momentum-stocks moving-average-crossover stock-price-movement stocks-moving-today